Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations.
about
Personalized treatment for advanced colorectal cancer: KRAS and beyondMolecular pathways: targeting the dependence of mutant RAS cancers on the DNA damage responseActivated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated ProteinsA yeast-based genomic strategy highlights the cell protein networks altered by FTase inhibitor peptidomimeticsPulmonary adenocarcinoma: a renewed entity in 2011Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC)Cancer genomics identifies regulatory gene networks associated with the transition from dysplasia to advanced lung adenocarcinomas induced by c-Raf-1.Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs.Driven to death: Inhibition of farnesylation increases Ras activity and promotes growth arrest and cell death [corrected]Isoprenoids, small GTPases and Alzheimer's disease.Isoprenoid quantitation in human brain tissue: a validated HPLC-fluorescence detection method for endogenous farnesyl- (FPP) and geranylgeranylpyrophosphate (GGPP).Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.A new paradigm for the development of anticancer agents from natural productsOncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells.The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.Chaperone proteins and brain tumors: potential targets and possible therapeutics.Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level.KRAS mutant colorectal tumors: past and presentSynthesis of desthio prenylcysteine analogs: sulfur is important for biological activityExpressional Difference of RHEB, HDAC1, and WEE1 Proteins in the Stromal Tumors of the Breast and Their Significance in Tumorigenesis.Personalized medicine and treatment approaches in non-small-cell lung carcinoma.Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth.Farnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomasPhase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer.Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.A photoactive isoprenoid diphosphate analogue containing a stable phosphonate linkage: synthesis and biochemical studies with prenyltransferasesHow to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization.Farnesyl transferase inhibitor FTI-277 inhibits breast cell invasion and migration by blocking H-Ras activation.Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease.Smoking-associated lung cancer prevention by blockade of the beta-adrenergic receptor-mediated insulin-like growth factor receptor activation.Biochemical and docking analysis of substrate interactions with polyisoprenylated methylated protein methyl esterase.ProtozoaDB 2.0: A Trypanosoma Brucei Case Study.Simvastatin interacts synergistically with tipifarnib to induce apoptosis in leukemia cells through the disruption of RAS membrane localization and ERK pathway inhibition.Simvastatin stimulates apoptosis in cholangiocarcinoma by inhibition of Rac1 activity.Working together: Farnesyl transferase inhibitors and statins block protein prenylation.Fighting cancer by disrupting C-terminal methylation of signaling proteins.Metabolic Labeling with an Alkyne-modified Isoprenoid Analog Facilitates Imaging and Quantification of the Prenylome in Cells.The genomics of lung adenocarcinoma: opportunities for targeted therapies.H-ras localizes to cell nuclei and varies with the cell cycleTipifarnib in the treatment of acute myeloid leukemia.
P2860
Q26822817-7825F937-A418-423F-A948-5FFB3E9C44C9Q27014080-CFC599B6-24DC-49E9-852C-8E8C40EE2E78Q27027458-37BC694A-D6F0-4FBD-9D3C-DDBB87B100F5Q28382899-2E1BA0DB-F2BC-4BB9-A5A7-C6E4F379BDDEQ28395348-1CF7D09A-62D1-4992-B1D9-A7226AE2B90DQ30433431-52D4D598-8D96-412F-A2B2-741CC17FF836Q33509293-B1F51C84-77F9-445D-AFE1-D84FFE1C3E43Q33840802-71732B6E-AC17-4899-9113-0BC53715C4DDQ33843725-5BD44D87-2658-422D-A5B2-728C76F6C8FBQ33915441-D694DD1E-B793-4FDD-B729-A9C45524E3E1Q34071260-D0BE53E0-5D15-4C44-A32B-6D5975FDBDC9Q35091519-7DCD2EC4-F3A7-4B28-9610-6EC15190C2AFQ35214560-8F40319F-5D60-4561-8BDC-43BD9A989C40Q35756960-AF5CC5A1-4903-4360-9CB2-8DB06D13C355Q35774565-F6DAF48F-B076-4892-B7F2-5BFC4BE6ABEDQ35800492-3D951B36-8917-4B28-99B9-C18C9D2394FFQ35990656-5ADEC8B9-F3C6-42A5-92AE-3FFC08D78FC6Q36100844-3A88E00F-4241-41BA-8F6B-69AAFFB56802Q36107507-944E699E-692F-4176-9659-8AF9F66BEE78Q36343730-FA9E9C5A-8234-464D-AD96-3BCA4F8BB718Q36441548-3E223429-2C52-4F4B-840B-AC78C689D531Q36584173-39FCFAE4-D99A-4F38-BF1B-3B1C0958A3E4Q36693797-81821764-FF3E-49A1-B1FF-B2DE406EED28Q36740646-34BDA251-DE90-4722-B549-587E62021DFAQ36744817-DBAA7824-3353-49F4-B390-1A43AB617F8AQ36922830-5B373368-26DA-4F05-8B97-C82B1A564D7EQ37113976-8AB9E4FE-819E-467B-87A4-F58CDFA4B654Q37205817-3AECA2E7-5372-4290-B20C-4B4AFC245599Q37284331-6820A743-18C7-4EAA-90AA-913042BBD421Q37688636-E5EC96C0-3BC8-4AAA-89B2-A981F9AEF7D5Q37758841-019A6AFC-407A-447B-A9D8-8E8C717896DDQ38670651-14D080F0-5AA5-4C71-8AA6-D8D2AC464080Q38952701-2F3E1968-243A-4ECF-B0E4-1A107BE0BA45Q39589202-269EFA50-2BF4-4729-B993-3FB2B2565238Q40149906-0563F467-7CBE-4E71-BB06-2E1D01AE5A02Q40553729-716276B1-6673-432B-8AED-64F74067C130Q41535966-E94E805C-C29E-4F67-AFAB-D9BB3396D26AQ41891513-29D74625-555B-4B0B-8FA2-1CF59BA50D4CQ42210981-B2BD857D-3BBF-4466-884A-17CD29613034Q42217527-CCE7E8C4-BB7E-43A6-8425-8B14805C9109
P2860
Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Farnesyltransferase inhibitors ...... l and clinical investigations.
@ast
Farnesyltransferase inhibitors ...... l and clinical investigations.
@en
type
label
Farnesyltransferase inhibitors ...... l and clinical investigations.
@ast
Farnesyltransferase inhibitors ...... l and clinical investigations.
@en
prefLabel
Farnesyltransferase inhibitors ...... l and clinical investigations.
@ast
Farnesyltransferase inhibitors ...... l and clinical investigations.
@en
P2093
P1433
P1476
Farnesyltransferase inhibitors ...... al and clinical investigations
@en
P2093
Anjali K Gupta
Eric J Bernhard
Ruth J Muschel
Stephen M Hahn
Thomas B Brunner
W Gillies McKenna
P304
P407
P577
2003-09-01T00:00:00Z